European Archives - Page 413 of 1050 - European Medical Journal

Interview: Grant Blashki

Grant Blashki- Associate Professor, Nossal Institute for Global Health, University of Melbourne, Victoria, Australia; Adjunct Associate Pr…

Interview: Karly Hampshire

Karly Hampshire Medical Student, University of California, San Francisco, USA; Founder and Co-director, Planetary Health Report Card; Fell…

Demystifying the Discussion of Sequencing Panel Size in Oncology Genetic Testing

Clinical laboratories worldwide are implementing next-generation sequencing (NGS) to identify cancer genomic variants and ultimately…

Lymphoepithelial Cysts of the Pancreas: CT and MRI Features

Objective: Describe CT and MRI features of the lymphoepithelial cyst (LEC) of the pancreas.Methods: The authors identified 13 cases…

Emetogenicity of Chemotherapy Regimens and Recommended Prophylaxis: A Review of MASCC/ESMO Guidelines

This article reviews the impact of CINV, the emetogenic risk associated with different chemotherapy regimens in solid tumours and haematologic malignancies, and guideline-based recommendations for antiemetic prophylaxis according to emetogenic risk.

Total Plasma Exchange for Hypertriglyceridaemia Complicated by Acute Pancreatitis: A Case Report

Hypertriglyceridaemia pancreatitis (HGTP) accounts for 1–35% of acute pancreatitis (AP) cases.1 Acute pancreatitis is an acute…

The physics of pharmacovigilance

A highly-effective pharmacovigilance function is a rising value differentiator for pharmaceutical companies. Read to find out more about the challenges.

Management of patients with oncogene-driven NSCLC: the shift towards personalized medicine

Management of patients with oncogene-driven NSCLC: the shift towards personalized medicine

Discuss the importance of the implementation of biomarker testing in routine clinical practice and the current and future challenges…

Killing projects, drug discovery and career progression

This week, the GOLD team is joined by Eric Bouilloux, Chief Development Officer, Istesso, to talk about immunometabolism and pharma predictions.

The progress and pain points of patient centricity

The pharmaceutical industry views itself as increasingly patient centric, but do two patient advocates agree? In this roundtable discussion, they consider what the industry is doing well, and their views on how it could improve further